Creative Medical Technology (CELZ) said Friday that it received a notice of allowance from the US Patent and Trademark Office for ImmCelz for the treatment of heart failure and post-infarct pathological remodeling.
Once granted, the patent will be in effect until at least 2040, the biotechnology company said.
The patent has broad claims on using ImmCelz via a minimally invasive outpatient procedure to treat patients at risk of developing or who already have heart failure, the company said.
Shares of the company were up 4.5% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.